Redundancy of Mammalian Proteasome Beta Subunit Function During Endoplasmic Reticulum Associated Degradation
Overview
Authors
Affiliations
Misfolded proteins in the endoplasmic reticulum (ER) are degraded by N-terminal threonine proteases within the 26S proteasome. Each protease is formed by an activated beta subunit, beta5/X, beta1/Y, or beta2/Z, that exhibits chymotrypsin-like, peptidylglutamyl-peptide hydrolyzing, or trypsin-like activity, respectively. Little is known about the relative contribution of specific beta subunits in the degradation of endogenous protein substrates. Using active site proteasome inhibitors and a reconstituted degradation system, we now show that all three active beta subunits can independently contribute to ER-associated degradation of the cystic fibrosis transmembrane conductance regulator (CFTR). Complete inactivation (>99.5%) of the beta5/X subunit decreased the rate of ATP-dependent conversion of CFTR to trichloroacetic acid soluble fragments by only 40%. Similarly, proteasomes containing only active beta1/Y or beta2/Z subunits degraded CFTR at approximately 50% of the rate observed for fully functional proteasomes. Simultaneous inhibition (>93%) of all three beta subunits blocked CFTR degradation by approximately 90%, and inhibition of both protease and ATPase activities was required to completely prevent generation of small peptide fragments. Our results demonstrate both a conserved hierarchy (ChT-L > PGPH > or = T-L) as well as a redundancy of beta subunit function and provide insight into the mechanism by which active site proteasome inhibitors influence degradation of endogenous protein substrates at the ER membrane.
Blunting Neuroinflammation by Targeting the Immunoproteasome with Novel Amide Derivatives.
Imbesi C, Ettari R, Irrera N, Zappala M, Pallio G, Bitto A Int J Mol Sci. 2023; 24(13).
PMID: 37445907 PMC: 10342075. DOI: 10.3390/ijms241310732.
On the Role of the Immunoproteasome in Protein Homeostasis.
Basler M, Groettrup M Cells. 2021; 10(11).
PMID: 34831438 PMC: 8621243. DOI: 10.3390/cells10113216.
Recent insights how combined inhibition of immuno/proteasome subunits enables therapeutic efficacy.
Basler M, Groettrup M Genes Immun. 2020; 21(5):273-287.
PMID: 32839530 DOI: 10.1038/s41435-020-00109-1.
Shi C, Zhu Y, Bruins L, de Campos C, Stewart W, Braggio E Mol Cancer Res. 2020; 18(10):1453-1464.
PMID: 32561655 PMC: 7541608. DOI: 10.1158/1541-7786.MCR-19-1026.
Strub M, McCray Jr P Genes (Basel). 2020; 11(5).
PMID: 32414011 PMC: 7288469. DOI: 10.3390/genes11050546.